

There is currently a unique opportunity to invest in a Swedish medtech company that develops the next generation of three dimensional cell culture systems using a technology that has several different applications and possible revenue streams.



Maximilian is the CEO and co-founder of Cellevate, and has played an important part in the technical development that has resulted in Cellevates electrospinning process and its applications over the last 6 years. Maximilian is the head of product development and is involved in stem cell research using nanofiber scaffolds at the Biomedical Center (BMC) in Lund. He holds a Master's degree in Engineering, Engineering Nanoscience, with a specialization in Nano Biomedicine from Lund University, Sweden.



Albin is the CTO and co-founder of Cellevate, and has been working with nanoscience and nanofiber technology for the past 6 years and have experience with electrospinning, nanofiber manufacturing, medical applications and stem cell research. He is in charge of the development of Cellevates electrospinning process and technical development. He holds a Master's degree in Engineering, Engineering Nanoscience and Nano Biotechnology from the faculty of engineering at Lund University, Sweden.

Contact Information

info@cellevate.com
(+46) 736 33 33 90

Company Description

Cellevate is an innovative material company that develops the next generation of human tissue nano-architecture. Through a scalable manufacturing process, Cellevate creates scaffolds that mimic human tissue. The company was founded in 2014 with the vision to increase the effectiveness of pharma-development, while reducing, refining and replacing animal trials. Cellevate started as a research project at Lund University.

Problem and Solution

The cost per developed drug has increased during recent years. One of the main reasons is that the biological cells that are the subject to pharmacological research experience different environment during the different stages of the development. Meanwhile, the ethical approval costs of animal trials are growing. Cellevate creates nanofiber materials that mimics human tissue, thereby increasing the relevance of the testing environment. They are incorporated in conventional cell culturing plates that already integrated in the workflow of the researcher. The cells cultured in the plates show more natural responses in terms of adhesion, proliferation, differentiation etc.

Traction and Market

Cellevate currently has over 20 satisfied customers worldwide and are expecting most of them to increase their demand going forward. Cellevate deliver about 10 plates per month with a target rate of 100 plates per month the end of 2018.

The cell culture market is estimated to grow to 18,6B USD by 2020. A subset of the market is the 3D cell culture market which is the one the company is addressing. That market is about 10 percent of the total market, 2,2B USD. Cellevate is currently targeting academia, CROs, diagnostic companies, as well as pharma companies.

Investment Offer

Cellevate seeks investments of 4 MSEK at a 48 MSEK post-money valuation, corresponding to 8.3% of the company. The funds are planned to be raised from private investors that can contribute with, beside the funding, expertise, time and network to generate company value. The funds will mainly be used to market current products and support development projects.

